Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease

Study Title

A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease

Teva Identifier

ACR16 C008

ClinicalTrials.gov Identifier

NCT00665223

Study Status

Completed

Trial Condition(s)

Huntington's Disease

Interventions

Drug: ACR16 | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Click for participation criteria and map of study locations
neurology icon for clinical trials

Key Participation Requirements

Gender

Female, Male

Age Range

30 Years and older

Trial Duration

04/01/2008 - 06/01/2011

Phase

Phase 3

Study Type

Interventional